Effects of secretin on content of PGE2 and 6-keto PGF1 alpha in gastric mucosa. 1988

T Mine, and J Fujisaki, and K Akimoto, and S Yoshida, and Y Hasegawa, and E Ogata
Fourth Department of Internal Medicine, University of Tokyo School of Medicine, Japan.

To determine the involvement of prostaglandins in the action of secretin on the promotion of the healing process in injured gastric mucosa, the effect of secretin infusion on the content of PGE2 and 6-keto PGF1 alpha (a major metabolite of PGI2) in human gastric mucosa was investigated. Specimens of both normal and injured mucosa were obtained from each of the patients who underwent polypectomy a week prior to the study. The specimens were obtained before and 20 min after intravenous infusion of secretin [2 Crick, Harper and Raper (CHR) units/kg] or saline. The basal content of PGE2 in injured mucosa was three times higher than that in normal gastric mucosa. Secretin did not increase the PGE2 content of normal gastric mucosa. However, secretin induced a sevenfold increase in the PGE2 content of injured mucosa. The content of 6-keto PGF1 alpha was not affected by secretin. These results suggest that, in injured mucosa, PGE2 is involved in the healing process and in the action of secretin as well.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005753 Gastric Mucosa Lining of the STOMACH, consisting of an inner EPITHELIUM, a middle LAMINA PROPRIA, and an outer MUSCULARIS MUCOSAE. The surface cells produce MUCUS that protects the stomach from attack by digestive acid and enzymes. When the epithelium invaginates into the LAMINA PROPRIA at various region of the stomach (CARDIA; GASTRIC FUNDUS; and PYLORUS), different tubular gastric glands are formed. These glands consist of cells that secrete mucus, enzymes, HYDROCHLORIC ACID, or hormones. Cardiac Glands,Gastric Glands,Pyloric Glands,Cardiac Gland,Gastric Gland,Gastric Mucosas,Gland, Cardiac,Gland, Gastric,Gland, Pyloric,Glands, Cardiac,Glands, Gastric,Glands, Pyloric,Mucosa, Gastric,Mucosas, Gastric,Pyloric Gland
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012633 Secretin A peptide hormone of about 27 amino acids from the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level. (USAN and the USP Dictionary of Drug Names, 1994, p597) Secrepan,Secretin Citrate, Pig,Secretin Maleate, Pig,Secretin Pentacetate, Pig,Secretin Sulfate, Pig,Secretin, Pig,Secretin-KABI,Pig Secretin,Pig Secretin Citrate,Pig Secretin Maleate,Pig Secretin Pentacetate,Pig Secretin Sulfate,Secretin KABI,SecretinKABI
D014945 Wound Healing Restoration of integrity to traumatized tissue. Healing, Wound,Healings, Wound,Wound Healings
D015121 6-Ketoprostaglandin F1 alpha The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue. 6-Keto-PGF1 alpha,6-Oxo-PGF1 alpha,6-Oxoprostaglandin F1 alpha,6 Ketoprostaglandin F1 alpha,6 Keto PGF1 alpha,6 Oxo PGF1 alpha,6 Oxoprostaglandin F1 alpha,F1 alpha, 6-Ketoprostaglandin,F1 alpha, 6-Oxoprostaglandin,alpha, 6-Keto-PGF1,alpha, 6-Ketoprostaglandin F1,alpha, 6-Oxo-PGF1,alpha, 6-Oxoprostaglandin F1
D015232 Dinoprostone The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa. PGE2,PGE2alpha,Prostaglandin E2,Prostaglandin E2alpha,PGE2 alpha,Prepidil Gel,Prostaglandin E2 alpha,Prostenon,E2 alpha, Prostaglandin,E2, Prostaglandin,E2alpha, Prostaglandin,Gel, Prepidil,alpha, PGE2,alpha, Prostaglandin E2

Related Publications

T Mine, and J Fujisaki, and K Akimoto, and S Yoshida, and Y Hasegawa, and E Ogata
May 1992, Clinica chimica acta; international journal of clinical chemistry,
T Mine, and J Fujisaki, and K Akimoto, and S Yoshida, and Y Hasegawa, and E Ogata
December 1990, Prostaglandins, leukotrienes, and essential fatty acids,
T Mine, and J Fujisaki, and K Akimoto, and S Yoshida, and Y Hasegawa, and E Ogata
May 1990, Prostaglandins, leukotrienes, and essential fatty acids,
T Mine, and J Fujisaki, and K Akimoto, and S Yoshida, and Y Hasegawa, and E Ogata
March 1992, Thrombosis research,
T Mine, and J Fujisaki, and K Akimoto, and S Yoshida, and Y Hasegawa, and E Ogata
January 1987, The American journal of physiology,
T Mine, and J Fujisaki, and K Akimoto, and S Yoshida, and Y Hasegawa, and E Ogata
December 1998, Yao xue xue bao = Acta pharmaceutica Sinica,
T Mine, and J Fujisaki, and K Akimoto, and S Yoshida, and Y Hasegawa, and E Ogata
June 1986, Acta physiologica Scandinavica,
T Mine, and J Fujisaki, and K Akimoto, and S Yoshida, and Y Hasegawa, and E Ogata
August 1995, Prostaglandins,
T Mine, and J Fujisaki, and K Akimoto, and S Yoshida, and Y Hasegawa, and E Ogata
June 1983, Prostaglandins, leukotrienes, and medicine,
T Mine, and J Fujisaki, and K Akimoto, and S Yoshida, and Y Hasegawa, and E Ogata
September 1988, Arerugi = [Allergy],
Copied contents to your clipboard!